Brief Summary

This is an expanded access designed to provide access to apixaban for eligibleparticipants.

Status
Available
EA Type
Individual Patients
Interventions

Drug: Apixaban

Administered as directed by treating physician
Other Name: Eliquis

Eligibility Criteria

Inclusion Criteria:

- Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic
Anticoagulation for Thromboembolism Prevention

- Previously participated in the CV185-362 study and was on apixaban for 1 year or
until treatment was no longer required

Exclusion Criteria:

- Weight less than 5 kg or greater than 35 kg

Other inclusion/exclusion criteria apply

Eligibility Gender
All
Eligibility Age
Minimum: 28 Days ~ Maximum: 17 Years
Countries
United States
Locations

Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, United States

Investigator: Andrew Glatz, Site 0001

Contacts

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Investigators

Bristol-Myers Squibb, Study Director
Bristol-Myers Squibb

Sponsors / Collaborators
Bristol-Myers Squibb
NCT Number
NCT05187286
MeSH Terms
Apixaban